Apnimed releases positive topline Phase 3 results for LunAIRo, the second Phase 3 clinical trial of AD109, meeting its primary endpoint, highlighting that AD109 met the primary endpoint, demonstrating a reduction in apnea-hypopnea index (AHI, p
apnimed.com